cas 915087-24-0|| where to buy 2-Fluoro-N-methyl-4-nitrobenzamide

製品名:2-Fluoro-N-methyl-4-nitrobenzamide

IUPAC Name:2-fluoro-N-methyl-4-nitrobenzamide

包装単位	有効在庫	価格（USD）
CM274844-1g	in stock	ȡȐȺ
CM274844-5g	in stock	Ƕȡŵ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 915087-24-0 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:915087-24-0; 分子式:C8H7FN2O3; 融点:-; SMILESコード:O=C(NC)C1=CC=C([N+]([O-])=O)C=C1F; 密度:

: カタログ番号:CM274844; 分子量:198.15; 沸点:337.1±32.0°C at 760 mmHg; MDL番号:MFCD09909407; 保管方法:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Enzalutamide; Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.